The Know ALL website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know ALL cannot guarantee the accuracy of translated content. Know ALL and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How I treat relapsed or refractory ALL
Nicola Gökbuget
July 18, 2023
At the 2023 Know ALL Community Meeting, Dr. Nicola Gökbuget, University Hospital Frankfurt, Frankfurt, DE, delivers an expert-led session on the topic of how I treat relapsed or refractory ALL.
Gökbuget begins by providing an overview of adult ALL, focusing on how ALL is measured and how relapsed/refractory ALL is defined. She then discusses the steps after detection of relapse and elaborates on the factors that impact treatment decisions and goals. Speaking on relapsed/refractory ALL, Gökbuget contrasts the primary therapeutic approaches between T-ALL and Philadelphia chromosome-positive/-negative B-ALL. She then outlines several specific targeted approaches using real-world data. Before closing, Gökbuget also evaluates the impact of CAR T-cell therapy in adult ALL.
